triazolam has been researched along with Cardiac Failure in 1 studies
Triazolam: A short-acting benzodiazepine used in the treatment of insomnia. Some countries temporarily withdrew triazolam from the market because of concerns about adverse reactions, mostly psychological, associated with higher dose ranges. Its use at lower doses with appropriate care and labeling has been reaffirmed by the FDA and most other countries.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rocha, A | 1 |
| Pinto, ACPN | 1 |
| Pachito, DV | 1 |
| Drager, LF | 1 |
| Lorenzi-Filho, G | 1 |
| Atallah, ÁN | 1 |
1 review available for triazolam and Cardiac Failure
| Article | Year |
|---|---|
Pharmacological treatment for central sleep apnoea in adults.
Topics: Acetazolamide; Adult; Aged; Apnea; Buspirone; Carbonic Anhydrase Inhibitors; Disorders of Excessive | 2023 |